Matches in Nanopublications for { ?s ?p "[Imatinib mesylate (Gleevec), a small molecule inhibitor of abl, kit, and platelet-derived growth factor receptor (PDGFR) tyrosine kinases, has been reported to be effective in the treatment of hypereosinophilic syndrome (HES) and a rare eosinophilia-associated chronic myeloid disorder (eos-CMD) characterized by the t(5;12)(q33;p13) cytogenetic abnormality.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- NP480163.RAXgQnDWCs91UqKXcZoyEx-3evOC0VUu9yXGz0t4NZ31E130_assertion description "[Imatinib mesylate (Gleevec), a small molecule inhibitor of abl, kit, and platelet-derived growth factor receptor (PDGFR) tyrosine kinases, has been reported to be effective in the treatment of hypereosinophilic syndrome (HES) and a rare eosinophilia-associated chronic myeloid disorder (eos-CMD) characterized by the t(5;12)(q33;p13) cytogenetic abnormality.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP480163.RAXgQnDWCs91UqKXcZoyEx-3evOC0VUu9yXGz0t4NZ31E130_provenance.
- NP338500.RAuH1vT6twe6n4ILZbULNNkF6awy4OGWX24SiaPewO3_8130_assertion description "[Imatinib mesylate (Gleevec), a small molecule inhibitor of abl, kit, and platelet-derived growth factor receptor (PDGFR) tyrosine kinases, has been reported to be effective in the treatment of hypereosinophilic syndrome (HES) and a rare eosinophilia-associated chronic myeloid disorder (eos-CMD) characterized by the t(5;12)(q33;p13) cytogenetic abnormality.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP338500.RAuH1vT6twe6n4ILZbULNNkF6awy4OGWX24SiaPewO3_8130_provenance.
- NP870511.RA4HGCdTR4QunODH90BuBLRtC7yhyupCgwM0T6Zz9m3AI130_assertion description "[Imatinib mesylate (Gleevec), a small molecule inhibitor of abl, kit, and platelet-derived growth factor receptor (PDGFR) tyrosine kinases, has been reported to be effective in the treatment of hypereosinophilic syndrome (HES) and a rare eosinophilia-associated chronic myeloid disorder (eos-CMD) characterized by the t(5;12)(q33;p13) cytogenetic abnormality.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP870511.RA4HGCdTR4QunODH90BuBLRtC7yhyupCgwM0T6Zz9m3AI130_provenance.
- NP908807.RAOt-CGjLlCNGWfHoIwCSwQ-hhbjRsAJ9CXXR_BvHcvPQ130_assertion description "[Imatinib mesylate (Gleevec), a small molecule inhibitor of abl, kit, and platelet-derived growth factor receptor (PDGFR) tyrosine kinases, has been reported to be effective in the treatment of hypereosinophilic syndrome (HES) and a rare eosinophilia-associated chronic myeloid disorder (eos-CMD) characterized by the t(5;12)(q33;p13) cytogenetic abnormality.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP908807.RAOt-CGjLlCNGWfHoIwCSwQ-hhbjRsAJ9CXXR_BvHcvPQ130_provenance.